Related Experiment Videos
Oral budesonide for lymphocytic colitis
A Van Gossum1, A Schmit, M O Peny
1Department of Gastroenterology, Erasme Hospital, Free University of Brussels, Belgium.
The American Journal of Gastroenterology
|February 19, 1998
Summary
Lymphocytic colitis, a rare cause of watery diarrhea, typically requires anti-inflammatory drugs. Oral budesonide effectively treated a severe, unresponsive case, offering a new therapeutic option.
Area of Science:
- Gastroenterology
- Coloproctology
- Inflammatory Bowel Disease Research
Background:
- Lymphocytic colitis is a rare colonic inflammatory condition.
- Characterized by chronic watery diarrhea and diagnosed via biopsy.
- Standard treatments include 5-aminosalicylic acid (5-ASA) and corticosteroids.
Observation:
- A female patient presented with severe lymphocytic colitis.
- The patient was unresponsive to 5-ASA therapy.
- Symptoms included persistent watery diarrhea.
Findings:
- Oral budesonide administration led to dramatic clinical improvement.
- Budesonide demonstrated efficacy in a refractory case of lymphocytic colitis.
- This suggests budesonide as a potential treatment for severe, unresponsive disease.
Implications:
- Budesonide may be a valuable therapeutic option for severe lymphocytic colitis.
- Further research into budesonide's role in treating refractory colitis is warranted.
- This case highlights the importance of considering alternative treatments when standard therapies fail.